[Should Helicobacter pylori be eradicated in patients with functional dyspepsia?].
Elizalde
I
I
Servicio de Aparato Digestivo, Hospital de Navarra, Pamplona.
Borda
F
F
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology*; D005765:Gastrointestinal Agents / Q000191:economics / Q000627:therapeutic use; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D016480:Helicobacter pylori; D006801:Humans
D000900:Anti-Bacterial Agents; D005765:Gastrointestinal Agents